Market Cap
US$142.4m
Last Updated
2019/09/21 00:47 UTC
Data Sources
Company Financials +
Executive Summary
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.
Snowflake
Fundamentals
Excellent balance sheet and slightly overvalued.
Risks
- ANGLE is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has ANGLE's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
ANPC.Y
1.1%
US Medical Equipment
-0.6%
US Market
1 Year Return
n/a
ANPC.Y
9.9%
US Medical Equipment
0.6%
US Market
No trading data on ANPC.Y.
No trading data on ANPC.Y.
Share holder returns
| ANPC.Y | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 1.1% | -0.6% |
| 30 Day | 0% | 0.6% | 2.2% |
| 90 Day | n/a | 2.9% | 1.1% |
| 1 Year | n/a | 10.8%9.9% | 2.9%0.6% |
| 3 Year | n/a | 70.1%64.9% | 44.6%35.2% |
| 5 Year | n/a | 138.9%111.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is ANGLE's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is ANGLE undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
ANGLE's share price is below the future cash flow value, and at a moderate discount (> 20%).
ANGLE's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
ANGLE is loss making, we can't compare its value to the US Medical Equipment industry average.
ANGLE is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for ANGLE, we can't assess if its growth is good value.
Price Based on Value of Assets
ANGLE is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is ANGLE expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
-5.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
ANGLE's revenue is expected to grow significantly at over 20% yearly.
ANGLE is not considered high growth as it is expected to be loss making for the next 1-3 years.
ANGLE's revenue growth is expected to exceed the United States of America market average.
Unable to compare ANGLE's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare ANGLE's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if ANGLE will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has ANGLE performed over the past 5 years?
-24.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
ANGLE does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare ANGLE's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare ANGLE's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if ANGLE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if ANGLE has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if ANGLE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is ANGLE's financial position?
Financial Position Analysis
ANGLE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ANGLE has no long term commitments.
Debt to Equity History and Analysis
ANGLE has no debt.
ANGLE currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Low level of unsold assets.
ANGLE has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
ANGLE has sufficient cash runway for 1.3 years based on current free cash flow.
ANGLE has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.5% each year.
Next Steps
Dividend
What is ANGLE's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate ANGLE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate ANGLE's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as ANGLE has not reported any payouts.
Unable to verify if ANGLE's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as ANGLE has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of ANGLE's salary, the management and board of directors tenure and is there insider trading?
1.8yrs
Average management tenure
CEO
Andrew David Newland (57yo)
0yrs
Tenure
UK£336,000
Compensation
Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...
CEO Compensation Analysis
Andrew David's remuneration is lower than average for companies of similar size in United States of America.
Andrew David's compensation has increased whilst company is loss making.
Management Age and Tenure
1.8yrs
Average Tenure
54yo
Average Age
The average tenure for the ANGLE management team is less than 2 years, this suggests a new team.
Board Age and Tenure
9.3yrs
Average Tenure
57yo
Average Age
The tenure for the ANGLE board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Andrew David Newland (57yo)
Founder
- Tenure: 0yrs
- Compensation: UK£336.00k
Ian Griffiths (54yo)
CFO, Finance Director
- Tenure: 15.5yrs
- Compensation: UK£216.00k
Daniel O'Shannessy
Chief Scientific Officer
- Tenure: 1.7yrs
Paul Smith
VP & Chief Executive Officer of ANGLE Biosciences Inc
- Tenure: 1.8yrs
Martin Cooke (50yo)
Director of Manufacturing & Regulatory Affairs
- Tenure: 1.7yrs
Michael O'Brien
Business Development Director
- Tenure: 5.8yrs
Greg Shaw
Scientific Advisor & Member of Scientific Advisory Board
- Tenure: 0yrs
Board Members
Harold Swerdlow
Member of Scientific Advisory Board
- Tenure: 0yrs
Garth Selvey (70yo)
Non-Executive Chairman
- Tenure: 12yrs
- Compensation: UK£20.00k
Andrew David Newland (57yo)
Founder
- Tenure: 0yrs
- Compensation: UK£336.00k
Ian Griffiths (54yo)
CFO, Finance Director
- Tenure: 15.5yrs
- Compensation: UK£216.00k
Ashok Venkitaraman
Member of Scientific Advisory Board
- Tenure: 0yrs
Brian Howlett (74yo)
Non-Executive Director
- Tenure: 6.7yrs
- Compensation: UK£20.00k
Clive Stanway
Member of Scientific Advisory Board
- Tenure: 0yrs
Adrian Newland
Member of Scientific Advisory Board
- Tenure: 0yrs
George Hvichia (57yo)
Member of Scientific Advisory Board
- Tenure: 1.7yrs
Jim Reuben
Member of Scientific Advisory Board
- Tenure: 4.3yrs
Greg Shaw
Scientific Advisor & Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
ANGLE plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ANGLE plc
- Ticker: ANPC.Y
- Exchange: OTCPK
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£142.429m
- Listing Market Cap: UK£177.921m
- Shares outstanding: 172.64m
- Website: https://www.angleplc.com
Number of Employees
Location
- ANGLE plc
- The Surrey Research Park
- 10 Nugent Road
- Guildford
- Surrey
- GU2 7AF
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AGL | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Mar 2004 |
| ANPC.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Mar 2004 |
| DWV | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Mar 2004 |
| ANPC.Y | OTCPK (Pink Sheets LLC) | SPONSONRED ADR | US | USD | Oct 2014 |
Biography
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tum ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 00:47 |
| End of Day Share Price | 2019/07/15 00:00 |
| Earnings | 2019/04/30 |
| Annual Earnings | 2019/04/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.